1921
Volume 87, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The role of in irritable bowel syndrome (IBS) is incompletely known. We aimed to investigate whether eradication of alleviates symptoms in IBS. Twenty-five positive IBS patients were treated with Metronidazole (MZ) or Tetracycline. The patients were mostly female (89%), and mean age (SD) was 35.1 (8.2) years. Microbiological response, evaluated 2 weeks post-treatment, was observed in 15 of 25 patients (60%), all by MZ. Clinical response, defined as adequate relief of symptoms, was observed in 7 of 22 patients (32%), all by MZ. In a logistic regression analysis, we found no significant association between clinical and microbiological response. This case study did not support our hypothesis of a simple association between and IBS. Some -infections were insufficiently treated by MZ. Further studies into the prevalence and effect of eradication of in IBS and into efficient treatments of are warranted.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2012.11-0761
2012-12-05
2017-09-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/87/6/1046.html?itemId=/content/journals/10.4269/ajtmh.2012.11-0761&mimeType=html&fmt=ahah

References

  1. Choung RS, Locke GR, III, 2011. Epidemiology of IBS. Gastroenterol Clin North Am 40: 110.[Crossref]
  2. Spiegel BM, , 2009. The burden of IBS: looking at metrics. Curr Gastroenterol Rep 11: 265269.[Crossref]
  3. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC, , 2006. Functional bowel disorders. Gastroenterology 130: 14801491.[Crossref]
  4. El-Serag HB, Olden K, Bjorkman D, , 2002. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 16: 11711185.[Crossref]
  5. Agarwal N, Spiegel BM, , 2011. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Am 40: 1119.[Crossref]
  6. Quigley EM, Bergman F, Bytzer P, Fried M, Hunt M, Hungin AP, , 2007. Systematic review on the management of irritable bowel syndrome in the European Union. Eur J Gastroenterol Hepatol 19: S11S37.[Crossref]
  7. Quigley EM, Bytzer P, Jones R, Mearin F, , 2006. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig Liver Dis 38: 717723.[Crossref]
  8. Thabane M, Kottachchi DT, Marshall JK, , 2007. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 26: 535544.[Crossref]
  9. Ghoshal UC, Ranjan P, , 2011. Post-infectious irritable bowel syndrome: the past, the present and the future. J Gastroenterol Hepatol 26 (Suppl 3): 94101.[Crossref]
  10. Jeffery IB, O'Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, Simren M, , 2011. An irritable bowel syndrome subtype defined by species-specific alterations in fecal microbiota. Gut 61: 9971006.[Crossref]
  11. Salonen A, de Vos WM, Palva A, , 2010. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 156: 32053215.[Crossref]
  12. Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM, , 2011. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141: 17921801.[Crossref]
  13. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S, , 2010. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 22: 512515.
  14. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS, , 2009. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 104: 10331049.[Crossref]
  15. Majewski M, McCallum RW, , 2007. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 52: 139142.
  16. Pimentel M, Chow EJ, Lin HC, , 2003. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98: 412419.
  17. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y, , 2006. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145: 557563.[Crossref]
  18. Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y, , 2006. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 51: 12971301.[Crossref]
  19. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP, , 2011. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364: 2232.[Crossref]
  20. Esposito I, de Leone A, Di Gregorio S, Giaquinto S, de Magistris L, Ferrieri A, Riegler G, , 2007. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol 13: 60166021.[Crossref]
  21. Menees SB, Maneerattannaporn M, Kim HM, Chey WD, , 2012. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 107: 2835.[Crossref]
  22. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I, , 2006. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101: 326333.[Crossref]
  23. Barratt JL, Harkness J, Marriott D, Ellis JT, Stark D, , 2011. A review of Dientamoeba fragilis carriage in humans: several reasons why this organism should be considered in the diagnosis of gastrointestinal illness. Gut Microbes 2: 312.[Crossref]
  24. Stark D, Barratt J, Roberts T, Marriott D, Harkness J, Ellis J, , 2010. A review of the clinical presentation of dientamoebiasis. Am J Trop Med Hyg 82: 614619.[Crossref]
  25. Lagace-Wiens PR, VanCaeseele PG, Koschik C, , 2006. Dientamoeba fragilis: an emerging role in intestinal disease. CMAJ 175: 468469.[Crossref]
  26. Johnson EH, Windsor JJ, Clark CG, , 2004. Emerging from obscurity: biological, clinical, and diagnostic aspects of Dientamoeba fragilis . Clin Microbiol Rev 17: 553570.[Crossref]
  27. Stensvold CR, Lewis HC, Hammerum AM, Porsbo LJ, Nielsen SS, Olsen KE, Arendrup MC, Nielsen HV, Molbak K, , 2009. Blastocystis: unravelling potential risk factors and clinical significance of a common but neglected parasite. Epidemiol Infect 137: 16551663.[Crossref]
  28. de Wit MA, Koopmans MP, Kortbeek LM, van Leeuwen NJ, Vinje J, van Duynhoven YT, , 2001. Etiology of gastroenteritis in sentinel general practices in the Netherlands. Clin Infect Dis 33: 280288.[Crossref]
  29. Stark D, van Hal S, Marriott D, Ellis J, Harkness J, , 2007. Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis. Int J Parasitol 37: 1120.[Crossref]
  30. Stark D, Beebe N, Marriott D, Ellis J, Harkness J, , 2005. Prospective study of the prevalence, genotyping, and clinical relevance of Dientamoeba fragilis infections in an Australian population. J Clin Microbiol 43: 27182723.[Crossref]
  31. Girginkardesler N, Coskun S, Cüneyt Balcioğlu I, Ertan P, Ok UZ, , 2003. Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole. Clin Microbiol Infect 9: 110113.[Crossref]
  32. Colea A, Silard R, Panaitescu D, Florescu P, Roman N, Capraru T, , 1980. Studies on Dientamoeba fragilis in Romania. II. Incidence of Dientamoeba fragilis in healthy persons. Arch Roum Pathol Exp Microbiol 39: 4953.
  33. Borody TJ, Warren EF, Wettstein A, Robertson G, Recabarren P, Fontela A, Herdman K, Surace R, , 2002. Eradication of Dientamoeba fragilis can resolve IBS-like symptoms. J Gastroenterol Hepatol 17: A103.[Crossref]
  34. Stark DJ, Beebe N, Marriott D, Ellis JT, Harkness J, , 2006. Dientamoebiasis: clinical importance and recent advances. Trends Parasitol 22: 9296.[Crossref]
  35. Yakoob J, Jafri W, Beg MA, Abbas Z, Naz S, Islam M, Khan R, , 2010. Blastocystis hominis and Dientamoeba fragilis in patients fulfilling irritable bowel syndrome criteria. Parasitol Res 107: 679684.[Crossref]
  36. Jimenez-Gonzalez DE, Martinez-Flores WA, Reyes-Gordillo J, Ramirez-Miranda ME, Arroyo-Escalante S, Romero-Valdovinos M, Stark D, Souza-Saldivar V, Martinez-Hernandez F, Flisser A, Olivo-Diaz A, Maravilla P, , 2012. Blastocystis infection is associated with irritable bowel syndrome in a Mexican patient population. Parasitol Res 110: 12691275.[Crossref]
  37. Engsbro AL, Bytzer P, , 2011. Diagnostic strategies in patients suspected of irritable bowel syndrome. Gut 60 (Suppl 3): A58.
  38. Stensvold CR, Arendrup MC, Jespersgaard C, Molbak K, Nielsen HV, , 2007. Detecting Blastocystis using parasitologic and DNA-based methods: a comparative study. Diagn Microbiol Infect Dis 59: 303307.[Crossref]
  39. Stensvold CR, Nielsen SD, Badsberg JH, Engberg J, Friis-Moller N, Nielsen SS, Nielsen HV, Friis-Moller A, , 2011. The prevalence and clinical significance of intestinal parasites in HIV-infected patients in Denmark. Scand J Infect Dis 43: 129135.[Crossref]
  40. Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ, , 2007. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 5: 534540.[Crossref]
  41. Nagata N, Marriott D, Harkness J, Ellis JT, Stark D, , 2012. In vitro susceptibility testing of Dientamoeba fragilis . Antimicrob Agents Chemother 56: 487494.[Crossref]
  42. Verweij JJ, Mulder B, Poell B, van Middelkoop D, Brienen EA, van Lieshout L, , 2007. Real-time PCR for the detection of Dientamoeba fragilis in fecal samples. Mol Cell Probes 21: 400404.[Crossref]
  43. Yang J, Scholten T, , 1977. Dientamoeba fragilis: a review with notes on its epidemiology, pathogenicity, mode of transmission, and diagnosis. Am J Trop Med Hyg 26: 1622.
  44. Cuffari C, Oligny L, Seidman EG, , 1998. Dientamoeba fragilis masquerading as allergic colitis. J Pediatr Gastroenterol Nutr 26: 1620.[Crossref]
  45. Kurt O, Girginkardesler N, Balcioglu IC, Ozbilgin A, Ok UZ, , 2008. A comparison of metronidazole and single-dose ornidazole for the treatment of dientamoebiasis. Clin Microbiol Infect 14: 601604.[Crossref]
  46. Oxner RB, Paltridge GP, Chapman BA, Cook HB, Sheppard PF, , 1987. Dientamoeba fragilis: a bowel pathogen? N Z Med J 100: 6465.
  47. Preiss U, Ockert G, Broemme S, Otto A, , 1991. On the clinical importance of Dientamoeba fragilis infections in childhood. J Hyg Epidemiol Microbiol Immunol 35: 2734.
  48. Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ, , 2007. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 5: 534540.[Crossref]
  49. Spiegel B, Camilleri M, Bolus R, Andresen V, Chey WD, Fehnel S, Mangel A, Talley NJ, Whitehead WE, , 2009. Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology 137: 19441953.[Crossref]
  50. Mangel AW, Bornstein JD, Hamm LR, Buda J, Wang J, Irish W, Urso D, , 2008. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 28: 239249.[Crossref]
  51. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA, , 2005. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 100: 115123.[Crossref]
  52. Drossman DA, Danilewitz M, Naesdal J, Hwang C, Adler J, Silberg DG, , 2008. Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome. Am J Gastroenterol 103: 25622569.[Crossref]
  53. Bosman DK, Benninga MA, van de Berg P, Kooijman GC, van Gool T, , 2004. Dientamoeba fragilis: possibly an important cause of persistent abdominal pain in children. Ned Tijdschr Geneeskd 148: 575579.
  54. Butler WP, , 1996. Dientamoeba fragilis. An unusual intestinal pathogen. Dig Dis Sci 41: 18111813.[Crossref]
  55. Dardick KR, , 1983. Tetracycline treatment of Dientamoeba fragilis . Conn Med 47: 6970.
  56. Millet V, Spencer MJ, Chapin M, Stewart M, Yatabe JA, Brewer T, Garcia LS, , 1983. Dientamoeba fragilis, a protozoan parasite in adult members of a semicommunal group. Dig Dis Sci 28: 335339.[Crossref]
  57. Norberg A, Nord CE, Evengard B, , 2003. Dientamoeba fragilis–a protozoal infection which may cause severe bowel distress. Clin Microbiol Infect 9: 6568.[Crossref]
  58. Spencer MJ, Garcia LS, Chapin MR, , 1979. Dientamoeba fragilis. An intestinal pathogen in children? Am J Dis Child 133: 390393.[Crossref]
  59. Spencer MJ, Chapin MR, Garcia LS, , 1982. Dientamoeba fragilis: a gastrointestinal protozoan infection in adults. Am J Gastroenterol 77: 565569.
  60. Vandenberg O, Souayah H, Mouchet F, Dediste A, van Gool T, , 2007. Treatment of Dientamoeba fragilis infection with paromomycin. Pediatr Infect Dis J 26: 8890.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2012.11-0761
Loading
/content/journals/10.4269/ajtmh.2012.11-0761
Loading

Data & Media loading...

  • Received : 06 Dec 2011
  • Accepted : 09 Sep 2012

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error